Eli Lilly & Co: (NYSE: LLY)

(U.S: NYSE) As of Apr 23 04:00 PM ET

 Add to portfolio

$59.56 USD

-0.47 (-0.78%)

Volume: 6,548,278

Zacks Rank : 3-Hold [?]     #3    

Brokerage Reports

Search for reports:

0 items in cart

LILLY ELI & CO [LLY]

Reports for Purchase

Showing records 1 - 20 ( 54 total )

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 1

03/11/2014

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 2

01/31/2014

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 3

12/13/2013

Company Report

Pages: 11

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 4

10/24/2013

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 5

09/16/2013

Industry Report

Pages: 13

PCSK9 Deep Dive; It?s a Horse Race, but Likely More than One Winner

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 50.00

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 6

09/03/2013

Company Report

Pages: 11

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 7

07/25/2013

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 8

06/06/2013

Company Report

Pages: 12

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 9

04/25/2013

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 10

03/22/2013

Company Report

Pages: 12

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 11

01/30/2013

Company Report

Pages: 7

The Zyprexa Patent Expiration Has Largely Run Its Course

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 12

01/30/2013

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 13

12/12/2012

Company Report

Pages: 11

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 14

10/26/2012

Company Report

Pages: 7

Third Quarter Results

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 15

10/25/2012

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 16

09/04/2012

Industry Report

Pages: 10

Health Care Looking Solid Ahead of Election

Provider: DREXEL HAMILTON, LLC

Analyst: SINE B

Price: 25.00

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 17

09/03/2012

Company Report

Pages: 11

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 18

07/26/2012

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 19

07/25/2012

Company Report

Pages: 7

Solid Execution Overshadowed by Zyprexa Patent Expiration

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Company: LILLY ELI & CO

Industry: LARGE CAP PHARMA

Record: 20

06/22/2012

Company Report

Pages: 22

Griffin Securities Updates Coverage on Ligand Pharma. (LGND)

Provider: GRIFFIN SECURITIES, INC.

Analyst: MARKEY K

Price: 75.00